News Conference News STS 2020 TAVR Tussle at US Surgery Meeting Threatens to Widen Surgeon-Cardiologist Wedge Yael L. Maxwell January 29, 2020
News Features ‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry Michael O'Riordan January 10, 2020
News Daily News Most Secondary Prevention Patients Are Eligible for Multiple Drugs Michael O'Riordan January 03, 2020
News Daily News FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl Michael O'Riordan November 14, 2019
News Daily News European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs Shelley Wood December 18, 2018
News Daily News FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now Michael O'Riordan November 01, 2018
News Daily News FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients Todd Neale October 12, 2018
News Conference News ACC 2018 Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues Michael O'Riordan March 11, 2018
News Daily News Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond Shelley Wood December 26, 2017
News Daily News First High-Sensitivity Troponin Assay Finally Comes to the United States Todd Neale January 24, 2017
News Daily News TAVR as an Option for Intermediate-Risk Patients: Physicians Respond Yael L. Maxwell August 24, 2016